Halozyme sees zero-to-minimal royalty hit from CMS IPAY 2029 proposed rule
Halozyme sees zero-to-minimal royalty hit from CMS IPAY 2029 proposed rule, on Jun 15, 2026. A company milestone for Halozyme (ENHANZE royalty portfolio for n/a): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Halozyme Therapeutics, Inc. HALO
- Drug
- ENHANZE royalty portfolio
- For
- n/a
- Stage
- n/a
- When
- Jun 15, 2026
- Source note
- Responding to the CMS Medicare Drug Price Negotiation proposed rule issued June 12, 2026, Halozyme said it projects zero to minimal royalty revenue impact through at least 2035 and no impact on its ability to sign new ENHANZE deals.
- Checked
- Checked by a person when it was added
- Source: prnewswire.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- HALO headlines on this site
Halozyme expects the FDA to decide on amivantamab + hyaluronidase-lpuj (RYBREVANT FASPRO, uses Halozyme ENHANZE) for head and neck squamous cell carcinoma (OrigAMI-4) in Q1 2027 (Jan–Mar) (no exact date yet). An approval lets the company start selling it in that market.
More details
- Entry
- FDA decision on RYBREVANT FASPRO (ENHANZE) sBLA in head and neck cancer (partner: J&J) · Regulatory approval
- Drug
- amivantamab + hyaluronidase-lpuj (RYBREVANT FASPRO, uses Halozyme ENHANZE)
- For
- head and neck squamous cell carcinoma (OrigAMI-4)
- Stage
- sBLA under FDA priority review
- When
- Q1 2027 · the company gave a window, not a day
- Source note
- J&J submitted the sBLA around May 2026; Halozyme management said FDA granted priority review (~6-month review clock), implying a decision around late 2026/early 2027. No exact PDUFA date has been publicly announced.
- Checked
- Checked by a person when it was added
- Verify it
- Source: fool.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- Drugs@FDA ↗ — search the drug name for approval letters
- HALO headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
First Hypercon platform clinical trial starts, expected in the first half of 2027 (no exact date yet). A company milestone for Halozyme (Hypercon high-concentration formulation platform for undisclosed partner programs (incl. Vertex collaboration)): a step in the program rather than a decision or a data readout.
More details
- Entry
- First Hypercon platform clinical trial starts · Company milestone
- Drug
- Hypercon high-concentration formulation platform
- For
- undisclosed partner programs (incl. Vertex collaboration)
- Stage
- Clinical starts
- When
- H1 2027 · the company gave a window, not a day
- Source note
- Halozyme management guidance on Q2 2026 call: "First Hypercon clinical starts in the first half of 2027."
- Checked
- Checked by a person when it was added
- Verify it
- Source: fool.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- HALO headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page